Multiomics Services Market Size & Growth Forecast 2027–2036, By Segments (End-use, Application, Service, Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Multiomics Services Market size stood at USD 1.45 billion in 2026 and is predicted to grow at a 18.1% CAGR from 2027 to 2036, crossing USD 7.65 billion by 2036. The industry revenue for 2027 is calculated at USD 1.68 billion.
Get more details on this report
Request Free Sample ReportMultiomics Services Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 42.54% market share in 2026, supported by advanced life sciences infrastructure, established genomics and proteomics capabilities, and demand for integrated biological analysis in drug discovery and precision medicine.
- Asia Pacific is expected to grow fastest as life sciences research, biotechnology activity, and investments in genomics and precision medicine increase demand for integrated omics analysis, biomarker identification, and personalized healthcare research.
Segment Momentum
- Pharmaceutical and biotechnology companies accounted for 48.09% of the market in 2026, driven by demand for integrated molecular insights that support biomarker identification, therapeutic target discovery, disease characterization, and precision medicine research.
- Drug discovery and development accounted for 38.29% of the market in 2026 and is also the fastest-growing application segment, as researchers use integrated molecular data to identify targets, characterize disease pathways, evaluate drug responses, and advance targeted therapies.
Market Expansion Drivers
- Multiomics-driven research.
- Clinical diagnostic integration.
- Long-term precision medicine.
Leading Market Participants
- Prominent players in the multiomics services market include Thermo Fisher Scientific (USA), Illumina (USA), BGI Genomics (China), Qiagen (Netherlands), Eurofins Scientific (Luxembourg), GenScript (China), Novogene (China), Roche Diagnostics (Switzerland), Agilent Technologies (USA), Macrogen (South Korea).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.45 billion
- 2027 Estimated Market Size: USD 1.68 billion
- Projected Market Size: USD 7.65 billion by 2036
- Growth Forecast: 18.1% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: End-use (Pharmaceutical and Biotechnology Companies) | Application (Drug Discovery & Development) | Service (Research Services) | Type (Bulk Multiomics)
- Emerging Opportunity Segment: End-use (Pharmaceutical and Biotechnology Companies) | Application (Drug Discovery & Development) | Service (Research Services) | Type (Bulk Multiomics)
Market Growth Drivers and Industry Trends
Multiomics-driven research
The increasing use of multiomics-driven research is supporting market growth by enabling researchers to examine biological systems through multiple molecular layers in an integrated manner. Combining genomic, transcriptomic, proteomic, metabolomic, and other datasets can provide a more comprehensive understanding of disease mechanisms, biological pathways, and therapeutic responses. Growing demand for deeper biological insights is encouraging research organizations to adopt specialized multiomics services for complex discovery and translational research programs.
Clinical diagnostic integration
The integration of multiomics technologies into clinical diagnostics is creating new opportunities for service providers by supporting more comprehensive approaches to disease characterization and patient assessment. Multiomics analysis can help identify molecular signatures and biological patterns that may complement conventional diagnostic approaches. As healthcare systems increasingly emphasize personalized and data-driven diagnosis, the incorporation of multiomics into clinical research and diagnostic workflows is contributing to broader adoption of these services.
Long-term precision medicine
The continued development of precision medicine is driving demand for multiomics services by enabling a more detailed understanding of individual biological characteristics and disease variability. Multiomics approaches can integrate diverse molecular information to support patient stratification, biomarker discovery, treatment selection, and monitoring of therapeutic responses. As healthcare moves toward increasingly personalized treatment strategies, the ability to generate integrated molecular profiles is expected to remain an important driver of long-term demand for multiomics services.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Multiomics-driven research | 6% | Short term (≤ 2 yrs) | North America; Europe | Medium | Moderate |
| Clinical diagnostic integration | 5% | Medium term (2–5 yrs) | Europe; Asia Pacific | High | Moderate |
| Long-term precision medicine | 3% | Long term (5+ yrs) | North America; Asia Pacific | Medium | Slow |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America accounted for a 42.54% share of the multiomics services market in 2026, supported by advanced life sciences infrastructure, strong research capabilities, and growing adoption of integrated biological analysis technologies. Research institutions, pharmaceutical organizations, biotechnology companies, and healthcare providers are increasingly using multiomics approaches to understand complex biological systems and support advances in drug discovery, biomarker identification, and precision medicine. The region benefits from established genomics and proteomics capabilities, sophisticated research infrastructure, and increasing demand for comprehensive biological data analysis. Growing investments in personalized healthcare and translational research are further supporting the use of integrated omics services. Additionally, advances in data analytics and bioinformatics are enabling researchers to combine information from multiple biological layers, strengthening the role of multiomics services across research and healthcare applications.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is emerging as the fastest-growing region in the multiomics services market, impelled by expanding life sciences research, improving healthcare infrastructure, and increasing investments in genomics and precision medicine. Research organizations and healthcare institutions are increasingly adopting advanced omics technologies to investigate disease mechanisms, identify biomarkers, and support personalized treatment approaches. Growing biotechnology activity and expanding research capabilities are creating greater demand for integrated genomic, transcriptomic, proteomic, and other biological analysis services. Government support for life sciences research and the development of advanced healthcare technologies is further encouraging regional adoption. In addition, increasing awareness of precision medicine and the growing availability of sophisticated sequencing and analytical capabilities are creating significant opportunities for multiomics service providers across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Translational MultiomicsThe U.S. multiomics services market is prioritizing integrated genomic, transcriptomic, proteomic, and metabolomic workflows for drug discovery and translational research. Service providers are focusing on scalable data analysis, biomarker discovery, and seamless integration with pharmaceutical and biotechnology research programs.
Germany 🇩🇪
Precision Research IntegrationGermany is emphasizing multiomics services that connect molecular profiling with precision medicine, clinical research, and pharmaceutical development. Priorities include reproducible workflows, high-quality sample processing, advanced bioinformatics, and secure handling of complex datasets across research institutions and industry programs.
Japan 🇯🇵
Advanced Molecular ProfilingJapan is applying multiomics services to disease research, biomarker development, and precision healthcare initiatives. Demand is centered on high-quality sequencing and molecular profiling, integrated analytical platforms, and specialized bioinformatics capable of translating complex biological data into actionable research findings.
South Korea 🇰🇷
Integrated Omics AnalyticsSouth Korea is strengthening multiomics capabilities across biotechnology, pharmaceutical research, and precision medicine applications. Service priorities include integrated sequencing and proteomic workflows, automated data analysis, and scalable platforms that support biomarker identification and faster interpretation of complex molecular datasets.
France 🇫🇷
Clinical Multiomics TranslationFrance is focusing multiomics services on translational research, biomarker validation, and precision medicine applications. Providers are positioned to support pharmaceutical and academic programs requiring integrated molecular datasets, robust bioinformatics, and reproducible analytical workflows that can bridge discovery research and clinical development.
Italy 🇮🇹
Specialized Omics ServicesItaly is developing multiomics demand around specialized research services supporting oncology, rare diseases, drug discovery, and biomedical research. Market priorities include access to advanced analytical capabilities, outsourced bioinformatics expertise, and integrated workflows that allow research organizations to expand omics programs without extensive internal infrastructure.
Multiomics Services Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Pharmaceutical and Biotechnology Companies (Largest & Fastest-Growing Segment)
The pharmaceutical and biotechnology companies end-use segment accounted for the largest share of 48.09% in the multiomics services market in 2026 and is also expected to register the fastest growth during the forecast period. The strong position of pharmaceutical and biotechnology companies is primarily driven by the growing use of integrated biological data across genomics, transcriptomics, proteomics, metabolomics, and other omics disciplines to obtain a more comprehensive understanding of disease mechanisms and biological processes. Multiomics services enable researchers to integrate information from multiple molecular layers, supporting biomarker identification, disease characterization, therapeutic target discovery, and evaluation of treatment responses. The increasing complexity of drug development is encouraging pharmaceutical and biotechnology organizations to adopt advanced analytical approaches that can reveal biological relationships that may not be evident through individual omics techniques. Growing investment in precision medicine, biomarker research, and data-driven therapeutic development is further strengthening demand for specialized multiomics capabilities. As drug developers increasingly rely on integrated molecular insights to improve research efficiency and decision-making, pharmaceutical and biotechnology companies are expected to remain a major driver of market expansion.
Application Segment Analysis: Drug Discovery & Development (Largest & Fastest-Growing Segment)
The drug discovery & development application segment accounted for the largest share of 38.29% in the multiomics services market in 2026 and is also projected to experience the fastest growth during the forecast period. The increasing complexity of identifying effective therapeutic targets and understanding disease biology is driving greater adoption of multiomics approaches throughout drug development workflows. By integrating multiple molecular data types, researchers can investigate disease pathways more comprehensively, identify potential biomarkers, characterize therapeutic targets, and improve understanding of drug response mechanisms. Multiomics analysis can also support patient stratification and the development of more targeted treatment approaches, strengthening its relevance to precision medicine. The growing volume and complexity of biological datasets is further increasing the need for specialized analytical services capable of integrating and interpreting information across multiple molecular layers. As pharmaceutical and biotechnology research increasingly shifts toward data-intensive and biologically informed drug development, demand for multiomics services for drug discovery and development is expected to expand rapidly.
Service Segment Analysis: Research Services (Largest & Fastest-Growing Segment)
The research services segment represents the largest share of the multiomics services market in 2026 and is also expected to grow at the fastest CAGR during the forecast period. The strong demand for research services is supported by the increasing need for specialized expertise to generate, integrate, analyze, and interpret complex multiomics datasets. Pharmaceutical companies, biotechnology organizations, academic researchers, and other users often require advanced analytical capabilities to extract meaningful biological insights from large volumes of genomic, transcriptomic, proteomic, and metabolomic information. Outsourcing these activities to specialized service providers can provide access to advanced technologies and multidisciplinary expertise without requiring organizations to develop all capabilities internally. The growing adoption of multiomics in disease research, biomarker discovery, precision medicine, and therapeutic development is further expanding the range of research applications. As biological studies become increasingly multidimensional and data-intensive, demand for specialized research services is expected to continue strengthening, supporting both the leading position and rapid growth of this service segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Academic & Research Institutes, Pharmaceutical and Biotechnology Companies, Others | Pharmaceutical and Biotechnology Companies | Pharmaceutical and Biotechnology Companies |
| Application | Biomarker Discovery, Drug Discovery & Development, Synthetic Biology, Others | Drug Discovery & Development | Drug Discovery & Development |
| Service | Research Services, Data Analysis Services | Research Services | Research Services |
| Type | Single-cell Multiomics, Bulk Multiomics | Bulk Multiomics | Bulk Multiomics |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Providers in the multiomics services space are increasingly leveraging single-cell and spatial resolution platforms to uncover granular tissue architecture, though high operational costs and data complexity remain core adoption hurdles. Unlocking the true potential of these multi-layered datasets requires AI-driven bioinformatics pipelines capable of harmonizing disparate molecular layers without creating non-reproducible analytical black boxes. Crucially, analytical success is grounded upstream in scalable sample preparation workflows, where service providers must maintain strict cross-omics consistency across diverse tissue types and scaling batch volumes. To establish long-term commercial value, service vendors must bridge early-stage high-throughput biomarker discovery with rigorous clinical assay validation, turning high-dimensional exploratory signals into standardized, clinically actionable diagnostics.
Key companies in the multiomics services market:
- Thermo Fisher Scientific (USA)
- Illumina (USA)
- BGI Genomics (China)
- Qiagen (Netherlands)
- Eurofins Scientific (Luxembourg)
- GenScript (China)
- Novogene (China)
- Roche Diagnostics (Switzerland)
- Agilent Technologies (USA)
- Macrogen (South Korea)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific (USA) | |||||||
| Illumina (USA) | |||||||
| BGI Genomics (China) | |||||||
| Qiagen (Netherlands) | |||||||
| Eurofins Scientific (Luxembourg) | |||||||
| GenScript (China) | |||||||
| Novogene (China) | |||||||
| Roche Diagnostics (Switzerland) | |||||||
| Agilent Technologies (USA) | |||||||
| Macrogen (South Korea) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Novogene Europe | July 2026 | Novogene Europe expanded its single-cell RNA sequencing capabilities at its Cambridge Omics Centre, strengthening its analytical service offerings and broadening its overall omics service capabilities within the UK market. |
| Source BioScience | April 2025 | Source BioScience acquired Cambridge Clinical Laboratories for an undisclosed sum, expanding its clinical diagnostics capabilities and testing services. The transaction strengthens the company's position in genomic services and histopathology diagnostics by integrating Cambridge Clinical Laboratories into its existing operations. |
| Leica Biosystems | April 2025 | Leica Biosystems and Bio-Techne expanded their partnership to introduce protease-free workflows for automated spatial multiomics on the BOND RX instrument across the United States and Europe. This collaboration optimizes workflow efficiency, preserves tissue integrity, and supports advanced biomarker discovery for research and clinical applications. |
| Azenta, Inc. | May 2024 | Azenta opened a new Genomics Laboratory in Oxford, UK, extending the reach of its GENEWIZ Multiomics & Synthesis Solutions. This facility supports the regional expansion of genomics and multiomics service capabilities while establishing a stronger local operating footprint. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Multiomics Services Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Omics Combination | Genomics & Transcriptomics, Proteomics & Metabolomics, Genomics & Proteomics, Transcriptomics & Proteomics, Multi-Layer Multiomics |
| Sample Type | Tissue Samples, Blood and Other Biofluids, Cell Samples, Microbial Samples |
| Customer Engagement Model | Project-Based Services, Contract-Based Services, Outsourced End-to-End Services |
Multiomics Services Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Multiomics Study Design Strategies |
|
| Clinical Translation Pathways |
|
| Outsourcing & Service Provider Selection |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
How large is the multiomics services market?
What are the growth projections for the multiomics services industry?
How is multiomics adoption influencing research and clinical workflows?
Why is precision medicine creating sustained demand for multiomics services?
Why do pharmaceutical and biotechnology companies dominate the multiomics services market?
How is drug discovery and development driving growth in the multiomics services market?
How does North America maintain its leadership in the multiomics services market?
Why is Asia Pacific emerging as a major growth market for multiomics services?
Which companies are driving growth in the multiomics services landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook